Credit Available: AANP, ASWB, CME, NCPD
Enroll in this Course
Activity Description
This webinar will focus on treating adolescents and young adults (AYAs) with blood cancer, including an overview of blood cancers common in AYAs, treatment options, including new and emerging data and the role of clinical trials, and the management of short and long-term effects, as well as unique considerations for AYAs. A list of resources that you can provide to your patients, as well as additional education resources for you will also be provided.
Time to Complete Activity: 1.0 hour
This course is available from:
December 12, 2023 until June 11, 2025
Course Instructors
Target Audience
This activity is intended for hematologist/oncologists, nurses, social workers, and other healthcare professionals involved in the care of patients with blood cancer.
Course content level for social workers: beginner and intermediate
Educational Objectives
After completing this activity, the participant should be better able to:
-
- Describe blood cancers common in adolescent and young adults (AYAs)
- Identify signs and symptoms of common blood cancers in AYAs and diagnostic tests used
- Explain treatment options, including new and emerging data and the role of clinical trials
- Discuss the management of short and long-term effects, as well as unique considerations for AYAs
- List resources to support patients and their caregivers
Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.0 clinical continuing education credit.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.
Nurse Practitioner Continuing Education
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.25 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23116459. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
There is no commercial support associated with this CE activity.
Providers
This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.
Disclosure of Conflicts of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Sharon M. Castellino, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Bristol Myers Squibb
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Seagen Inc.
Unlabeled Uses in Pediatrics
Nivolumab
Brentuximab vedotin (BV) (approved in high-risk; front line)
Pembrolizumab (approved in rr/HL)
Julie Anna Wolfson, MD, MSHS, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Planner
Lauren Berger, MPH
The Leukemia & Lymphoma Society
Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.
About this Activity
Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.
- Resources for You
- Resources for Patients
- FREE CME and CE courses for healthcare professionals:www.LLS.org/CE
- Treating Blood Cancers: Podcast series for healthcare professionals: www.LLS.org/HCPpodcast. Experts discuss the latest developments in blood cancers, new and emerging treatment options, side-effect management, survivorship issues, and more.
- LLS Online Community: HCP, Patient/Survivor & Caregiver account types: www.LLS.org/community
- Safe and secure site dedicated to research and has been created to support those living with blood cancer, their closest family members and healthcare professionals.
- Clinical Trial Nurse Navigators: : Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team – www.LLS.org/navigation
- Information Resource Specialists: Nurses, social workers, and health educators who assist through treatment, financial, and social challenges. They offer up-to-date disease and treatment information – www.LLS.org/IRC
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Contact Us: https://www.lls.org/form/contact-us
- Live chat: www.LLS.org/InformationSpecialists
- Children and Young Adult Specific Resources: www.LLS.org/AYA
- Telephone and web education programs: www.LLS.org/Programs
- Education Videos: www.LLS.org/Educationvideos
- Podcasts: www.LLS.org/LLS-podcast
- Free booklets and fact sheets on disease, treatment and survivorship: www.LLS.org/Booklets
- Support resources: www.LLS.org/Support
- Financial assistance
- Co-Pay
- Travel Assistance
- Referral to medication access programs
- Patient Aid
- Urgent Need
- Veteran Dental Financial Assistance (Program partners in New York, North Carolina, and Texas; see website for additional location and application details)
- LLS regions
- LLS Community (social media platform)
- Weekly online chats (facilitated by oncology social workers)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- Nutrition Education Services Center (1:1 nutrition consultation with registered dietitians)
- Clinical Trial Support Center Nurse Navigators: Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team – www.LLS.org/navigation
- Information Resource Specialists: Nurses, social workers, and health educators who assist through treatment, financial, and social challenges. They offer up-to-date disease and treatment information – www.LLS.org/IRC
- Phone: (800) 955-4572, M-F, 9 am to 9 pm
- Contact Us: https://www.lls.org/form/contact-us
- Live chat: www.LLS.org/InformationSpecialists
- Financial assistance
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at (800)-955-4572.